Abstract 1950P
Background
Neoadjuvant therapy might improve excision and limb salvage rates in locally advanced soft tissue sarcomas (STS). This phase II trial aimed to investigate the safety and activity of neoadjuvant pegylated liposomal doxorubicin (PLD) plus anlotinib in local advanced STS.
Methods
In this prospective, single-center, single-arm phase II study, major eligible criteria were locally advanced, non-metastasis, treatment-naive STS, age at 14-75 years old, pathological stage IIb/III, ECOG PS 0-2. Patients received PLD (50mg/m2, IV, D1, Q3W) and anlotinib (12mg/d, PO, D8-21, Q3W) for 2∼4 cycles. The primary endpoint was objective response rate (ORR). Secondary endpoints included overall survival (OS), progression-free survival (PFS), pathological complete response (ypT0/is ypN0, pCR) and safety.
Results
From November 2020 to November 2022, 45 patients were recruited. The median age was 47 years (range, 15-75) and 19 were female. The predominant histologies included Spindle cell sarcoma 7 (15.56%), Myxofibrosarcoma 5 (11.11%), Myxoid liposarcoma 5 (11.11%), Malignant peripheral nerve sheath tumor 4 (8.89%), Synovial sarcoma 4 (8.89%), Leiomyosarcoma 3 (6.67%). Median treatment cycles of neoadjuvant therapy were 2 (range, 1-4). The ORR and DCR of 29 patients with at least one assessment as Choi criteria was 62.1% and 100%, respectively. Of 39 (86.67%) patients underwent radical resection, 33 (84.62%) patients had an R0 resection. With a median follow-up time of 11.47 months, the median OS were not reached. Median PFS was 14.19 months, and the 1-year OS rate was 84.23%. The limb salvage rates was observed in 39 (100%) patients. The most common adverse events (AEs) of all grade were mucositis oral 19 (42.22%), proteinuria 13 (28.89%), neutropenia 12 (26.67%), and leucopenia 11 (24.44%). Grade 3/4 AEs were 13 (28.89%). PLD plus Anlotinib was well tolerated without significant unexpected toxic effects.
Conclusions
PLD combined with Anlotinib showed a promising efficacy and acceptable toxicity for patients with locally advanced soft tissue sarcomas, suggesting a potential therapeutic option for this population.
Clinical trial identification
NCT04765228.
Editorial acknowledgement
Legal entity responsible for the study
Y. Chen and W. Sun.
Funding
CSPC Ouyi Pharmaceutical Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1939P - phase I clinical results of SQ3370, a doxorubicin-based click chemistry therapeutic in advanced solid tumor patients
Presenter: Sant Chawla
Session: Poster session 15
1940P - Deep molecular profiling of advanced synovial sarcoma as a basis for interventional clinical trials
Presenter: Richard Schlenk
Session: Poster session 15
1941P - Preliminary efficacy and safety of SHR-2554 in advanced epithelioid sarcoma: A phase II trial
Presenter: Haiyan Hu
Session: Poster session 15
1942P - Non-metastatic malignant phyllodes tumors of the breast (B-MPT): A retrospective analysis from a referral center
Presenter: Carmine Valenza
Session: Poster session 15
1944P - MAGE-A4 and NY-ESO-1 expression analysed in a synovial sarcoma tissue micro-array
Presenter: Lore De Cock
Session: Poster session 15
1945P - Diagnostic and therapeutic impact of liquid biopsy in soft tissue sarcomas: A case series
Presenter: Tarek Assi
Session: Poster session 15
1946P - Bladder primary sarcomas (BSar): A genomic landscape and clinical outcomes study
Presenter: ALINA BASNET
Session: Poster session 15
1947P - Predictors and outcomes of recurrent retroperitoneal liposarcoma: New insights into its recurrence patterns
Presenter: Huan Deng
Session: Poster session 15
1948P - Concordance of the pathological diagnosis between local institutional and central judgment in high-grade non-round-cell sarcomas: A supplementary analysis of JCOG1306
Presenter: Eisuke Kobayashi
Session: Poster session 15